College of Pharmacy, University of Florida, Gainesville, USA.
J Am Pharm Assoc (2003). 2012 Jan-Feb;52(1):34-42. doi: 10.1331/JAPhA.2012.10114.
To combine anchor- and distribution-based approaches to identify minimally important differences (MIDs) for the short-form six-dimension utility index (SF-6D) and to identify variables associated with self-reported health status change.
Descriptive, exploratory, nonexperimental study.
United States between April 1, 1999, and October 31, 1999.
2,317 participants of SADD-Sx (Study of Antihypertensive Drugs and Depressive Symptoms), aged 50 years or older and with hypertension and coronary artery disease.
Patients were randomized into a verapamil SR- or atenolol-led hypertensive treatment strategy and mailed baseline and 1-year surveys.
SF-6D utility scores for patients completing both surveys.
The pooled mean (±SD) MID change on the SF-6D of patients whose health status minimally changed was 0.035 ± 0.095. The anchor-based change scores had a median value of 0.036 (interquartile range -0.03 to 0.10). One-third and one-half of the SD of SF-6D change scores were 0.035 and 0.053, respectively. Whites were less likely to report minimally improved health status compared with nonwhites (odds ratio 0.59 [95% CI 0.40-0.88]). Change in SF-6D scores improved prediction of health status change.
We recommend using the MID range based on all patients combined (-0.03 to 0.10) to interpret SF-6D scores. These estimates can be used in conjunction with other measures of efficacy to determine meaningful changes. SF-6D demonstrates potential utility in predicting minimally important improvement or worsening among patients receiving different pharmacologic medications.
结合锚定和分布方法来确定简短六维度健康状况量表(SF-6D)的最小重要差异(MID),并确定与自我报告健康状况变化相关的变量。
描述性、探索性、非实验研究。
1999 年 4 月 1 日至 1999 年 10 月 31 日期间的美国。
年龄在 50 岁或以上、患有高血压和冠心病的 SADD-Sx(抗高血压药物和抑郁症状研究)的 2317 名参与者。
患者被随机分为维拉帕米 SR 或阿替洛尔主导的高血压治疗策略,并邮寄基线和 1 年调查。
完成两次调查的患者的 SF-6D 效用评分。
健康状况最小变化的患者 SF-6D 的平均(±SD)MID 变化为 0.035±0.095。基于锚定的变化评分中位数为 0.036(四分位距-0.03 至 0.10)。SF-6D 变化评分的三分之一和一半标准差分别为 0.035 和 0.053。与非白人相比,白人报告健康状况略有改善的可能性较小(比值比 0.59[95%置信区间 0.40-0.88])。SF-6D 评分的变化改善了健康状况变化的预测。
我们建议使用基于所有患者的 MID 范围(-0.03 至 0.10)来解释 SF-6D 评分。这些估计值可以与其他疗效衡量标准一起使用,以确定有意义的变化。SF-6D 在预测接受不同药物治疗的患者中最小重要改善或恶化方面具有潜在的效用。